Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy

Department of Endocrinology and Diabetology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.

To evaluate the consequences of growth hormone (GH) deficiency on bone mineral density and to evaluate the effects of GH substitution therapy, 68 adults (25 females and 43 males) aged 22-61 (mean 44.2 +/- 1.2) years with GH deficiency (GHD) were studied. Fifty-eight patients had panhypopituitarism, three had isolated GHD and in seven patients at least one additional pituitary function was affected. Twenty-one patients had childhood onset GHD. The patients were randomized to receive either GH in daily injections (0.125 IU.kg-1. week-1 for the first 4 weeks and subsequently 0.25 IU.kg-1. week-1) or placebo for 6 months. The trial continued as an open study with GH treatment for 6 to 12 months, with data presented as compiled data of 12 months of GH treatment in 64 patients. Bone mineral density (BMD) was measured by dual energy x-ray absorptiometry and bone turnover was assessed by serum markers of bone metabolism (osteocalcin, procollagen I peptide, cross-linked telopeptide of type I collagen and alkaline phosphatase activity), In women with adult onset GHD (N = 19) and in men with childhood onset GHD (N = 15), total body, spine and hip BMD was significantly reduced at baseline compared to Swedish age- and sex-matched control material. In men with adult onset of GHD (N = 28), BMD did not differ from male controls.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				G Gotherstrom, B-A Bengtsson, I Bosaeus, G Johannsson, and J Svensson Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 55 - 64. [Abstract] [Full Text] [PDF]

				N. Mauras, O. H. Pescovitz, V. Allada, M. Messig, M. P. Wajnrajch, B. Lippe, and on behalf of the Transition Study Group Limited Efficacy of Growth Hormone (GH) during Transition of GH-Deficient Patients from Adolescence to Adulthood: A Phase III Multicenter, Double-Blind, Randomized Two-Year Trial J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3946 - 3955. [Abstract] [Full Text] [PDF]

				M. Hayakawa, Y. Shimazaki, T. Tsushima, Y. Kato, K. Takano, K. Chihara, A. Shimatsu, and M. Irie Metabolic Effects of 20-Kilodalton Human Growth Hormone (20K-hGH) for Adults with Growth Hormone Deficiency: Results of an Exploratory Uncontrolled Multicenter Clinical Trial of 20K-hGH J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1562 - 1571. [Abstract] [Full Text] [PDF]

				Y. Kasukawa, D. J. Baylink, R. Guo, and S. Mohan Evidence that Sensitivity to Growth Hormone (GH) Is Growth Period and Tissue Type Dependent: Studies in GH-Deficient lit/lit Mice Endocrinology, September 1, 2003; 144(9): 3950 - 3957. [Abstract] [Full Text] [PDF]

				M. Bramnert, M. Segerlantz, E. Laurila, J. R. Daugaard, P. Manhem, and L. Groop Growth Hormone Replacement Therapy Induces Insulin Resistance by Activating the Glucose-Fatty Acid Cycle J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1455 - 1463. [Abstract] [Full Text] [PDF]

				C. Hoybye, A. Hilding, H. Jacobsson, and M. Thoren Metabolic Profile and Body Composition in Adults with Prader-Willi Syndrome and Severe Obesity J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3590 - 3597. [Abstract] [Full Text] [PDF]

				B. M. K. Biller, G. Sesmilo, H. B. A. Baum, D. Hayden, D. Schoenfeld, and A. Klibanski Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 970 - 976. [Abstract] [Full Text]

				A. G. Johansson, B. E. Engström, S. Ljunghall, F. A. Karlsson, and P. Burman Gender Differences in the Effects of Long Term Growth Hormone (GH) Treatment on Bone in Adults with GH Deficiency J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2002 - 2007. [Abstract] [Full Text]

				Y. J. H. Janssen, N. A. T. Hamdy, M. Frölich, and F. Roelfsema Skeletal Effects of Two Years of Treatment with Low Physiological Doses of Recombinant Human Growth Hormone (GH) in Patients with Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2143 - 2148. [Abstract] [Full Text]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]

				M. Thoren, A. Hilding, R. C. Baxter, M. Degerblad, I.-L. Wivall-Helleryd, and K. Hall Serum Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit as Serum Markers of Body Composition during Growth Hormone (GH) Therapy in Adults with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 223 - 228. [Abstract] [Full Text] [PDF]